|
kEUR |
2025 |
2024 |
|
|
|
|
|
Revenue at constant currency rates 1 |
390,628 |
336,653 |
|
Impact from changes in exchange rates compared to prior period |
-1,301 |
139 |
|
Revenue reported (IFRS) |
389,327 |
336,792 |
1 Revenue translated into the presentation currency, EUR, using the weighted average EUR currency exchange rate from the prior period.
|
|
2025 vs 2024 |
2024 vs 2023 |
|
|
|
|
|
Change in revenue reported (IFRS) (%) |
15.6% |
5.1% |
|
Change in revenue at constant currency rates (%) 1 |
16.0% |
5.1% |
1 The change is calculated as: (Current period's revenue at constant currencies) / (Prior period's revenue reported (IFRS)) - 1.
|
kEUR |
2025 |
2024 |
2021 |
|
|
|
|
|
|
Commercial revenue |
235,896 |
218,644 |
115,120 |
|
Development revenue, excl. revenue associated with the coronavirus pandemic |
153,431 |
118,148 |
103,812 |
|
Revenue associated with the coronavirus pandemic |
– |
– |
63,194 |
|
Revenue reported (IFRS) |
389,327 |
336,792 |
282,126 |
|
kEUR |
2025 |
2024 |
2021 |
|
|
|
|
|
|
Metabolic |
220,573 |
133,363 |
62,219 |
|
Oncologic |
39,359 |
56,245 |
40,189 |
|
Other, excl. revenue associated with the coronavirus pandemic |
129,395 |
147,184 |
116,524 |
|
Revenue associated with the coronavirus pandemic |
– |
– |
63,194 |
|
Revenue reported (IFRS) |
389,327 |
336,792 |
282,126 |
|
kEUR |
2025 |
2024 |
2021 |
|
|
|
|
|
|
Large pharma |
243,768 |
205,504 |
119,429 |
|
Biotech, excl. revenue associated with the coronavirus pandemic |
87,498 |
91,968 |
66,710 |
|
Other |
58,061 |
39,320 |
32,793 |
|
Revenue associated with the coronavirus pandemic |
– |
– |
63,194 |
|
Revenue reported (IFRS) |
389,327 |
336,792 |
282,126 |
|
kEUR |
2025 |
2024 |
|
|
|
|
|
Operating result (EBIT) |
8,689 |
-7,364 |
|
Depreciation, amortization and impairment charges (if any) |
38,066 |
32,714 |
|
EBITDA |
46,755 |
25,350 |
|
kEUR |
2025 |
2024 |
|
|
|
|
|
Operating result (EBIT) |
8,689 |
-7,364 |
|
Average 1 Net operating assets: |
|
|
|
Total non-current assets (average) |
464,719 |
395,420 |
|
Total current assets (average) |
326,549 |
327,412 |
|
Cash and cash equivalents (average) |
-71,433 |
-81,992 |
|
Total current liabilities (average) |
-190,518 |
-185,477 |
|
Average 1 Net operating assets |
529,317 |
455,363 |
|
Return on net operating assets (RONOA) |
1.6% |
-1.6% |
1 The average amounts are calculated as: (Current period's figures + prior period's figures) / 2.
|
kEUR |
2025 |
2024 |
|
|
|
|
|
Net cash flows from operating activities |
77,510 |
89,399 |
|
Acquisition of intangible assets |
-1,152 |
-1,217 |
|
Acquisition of property, plant and equipment |
-107,753 |
-85,751 |
|
Free Cash Flow |
-31,395 |
2,431 |
|
kEUR |
2025 |
2024 |
|
|
|
|
|
Cash and cash equivalents |
74,589 |
68,277 |
|
Interest-bearing liabilities (Total financial debt): |
|
|
|
Interest-bearing loans and borrowings (Non-current) |
-109,034 |
-39,420 |
|
Lease liabilities (Non-current) |
-15,979 |
-18,982 |
|
Other financial liabilities (Non-current) |
-9,435 |
-9,508 |
|
Interest-bearing loans and borrowings (Current) |
-544 |
-30,642 |
|
Lease liabilities (Current) |
-5,008 |
-5,073 |
|
Other financial liabilities (Current) |
-1,361 |
-1,266 |
|
Interest-bearing liabilities (Total financial debt) |
-141,361 |
-104,891 |
|
Net Cash / (debt) |
-66,772 |
-36,614 |
|
kEUR |
2025 |
2024 |
|
|
|
|
|
Property, plant and equipment assets capitalized |
108,806 |
86,777 |
|
Intangible assets capitalized |
1,172 |
1,062 |
|
Capital expenditures (Capex) |
109,978 |
87,839 |